alexa Bilirubin Nanoparticles As Nanomedicine For Liver Fibrosis Therapy
ISSN: 2167-0889

Journal of Liver
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th International Conference on Hepatology
April 27-28, 2017 Dubai, UAE

Poilil Surendran Suchithra, Reju George Thomas, Sejy Lee, Sangyong Jon and Yong Yeon Jeong
Chonnam National University Medical School, Korea
Korea Advanced Institute of Science and Technology, Korea
Posters & Accepted Abstracts: J Liver
DOI: 10.4172/2167-0889-C1-012
Bilirubin is hydrophobic in nature and polyethylene glycol (PEG; molecular weight, 2,000) was covalently attached to this compound via a stable amide bond resulting in PEGylated bilirubin (PEG-BR). PEG-BR is found to have ability to undergo a solubility switch from hydrophobic to hydrophilic in response to intrinsic ROS. PEG-BR is a novel nanovesicle system which is studied for its multi-stimuli-responsive mechanism utilized as ROS/drug-delivery carriers. Advanced liver fibrosis is a condition characterized by ROS stress and metabolical effects in hepatocytes. In our study, we use PEG-BR as a ROS quenching, anti-inflammatory agent which also have ability to load hydrophobic or hydrophilic drug against progression of fibrosis. We have developed liver fibrosis model in C3H/HeN mice by administering thioacetamide and ethanol. PEGBR was injected through intravenous route in 3 dosages for a period of 9 days. Finally, we analyzed hepatic histopathology and biochemical estimation, respectively. We observed a dosage dependent improvement of hepatic fibrosis and biochemical examination (AST/ALT ratio) in the PEG-BR treated group. PEG-BR nanovesicles might be useful in reduction of mice hepatic fibrosis model.

Poilil Surendran Suchithra has completed her MSc in Chemistry from Calicut University, India during 2011-2013. At present, she is pursuing her PhD under Prof. Yong Yeon Jeong developing hepatitis mice model therapy using nanoparticle as well as stem cell therapy and conducting pre-clinical testing at Clinical Vaccine R&D Centre of Chonnam National University Hwasun Hospital, South Korea.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version